BioSpace News Archive

Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™, the world’s only balloon-expandable, 3D single-piece aortic valve shaped to mimic the native human valve, today announced the U.S. Food and Drug Administration (FDA) has conditionally approved the DurAVR™ Transcatheter Heart Valve (THV; TAVR) System for investigational device exemption (IDE) application to commence an Early Feasibility Study (EFS).

The International Centers for Precision Oncology Foundation and Melbourne-based PreMIT Pty Ltd, announced a collaboration to develop a global network of Precision Oncology and Theranostics centers.

Bionaut Labs, the company that uses microscale robots to revolutionize the treatment of central nervous system (CNS) diseases and disorders, today announced $43.2M in a Series B round of financing led by Khosla Ventures, bringing the company’s total financing raised to date to $63.2 million.

On December 2, the Lennox-Gastaut Syndrome (LGS) Foundation will host its LGS Research Roundtable at the American Epilepsy Society’s (AES) annual meeting in Nashville, TN.

Therapeutic Solutions International (TSOI) announced today issuance of United States Patent # 11,504,4101 which in its broadest claim covers.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA.

VIDA Diagnostics, Inc. (VIDA), the leader in imaging intelligence, has announced the availability of VIDA Intelligence Portal 2.0, a major upgrade of its cloud native, AI-enabled Intelligence platform.

Shimadzu Medical Systems USA , a subsidiary of Shimadzu Corporation, receives an IMV ServiceTrak Award in the R/F Systems category.

CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise with competitive prices and fast turnarounds for researchers.

NeuroLogica Announces FDA 510(k) Clearance of BodyTom ® 64.